Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Analysts back buy-on-dips strategy as Nifty targets 24,450–24,800
Indian stock market analysts are optimistic, anticipating the Nifty to continue its upward trend. They suggest buying on dips around the 24,000-24,150 mark, with potential upside targets reaching 24,800. Several stocks, including Container Corporation of India, IndusInd Bank, Biocon, HDFC Asset Management Company, Shriram Finance, and Piramal Pharma, are highlighted as strong buy recommendations with specific price targets and stop-losses.
Health ministry issues proposal for one-year residual shelf life for imported drugs
The Union Health Ministry is proposing to relax import rules for medicines, requiring a minimum 12-month shelf life upon arrival instead of the current 60% of total shelf life. This move aims to simplify business operations and ensure medicine availability. The change, however, will not affect specialized drugs like biologicals and radiopharmaceuticals. Officials believe this will cut down wastage and improve inventory management, ultimately benefiting patients.
CCI clears TVS Group's acquisition of PGIM India AMC, Temasek-Romsons deal
India's fair trade regulator CCI has given the green light for TVS Group entities to acquire PGIM India Asset Management. The regulator also cleared Temasek's investment in medical devices maker Romsons Group. These approvals pave the way for significant business consolidations in the financial and healthcare sectors. The deals involve substantial stake acquisitions and restructuring.
Sai Life, Laurus Labs hit new highs; stocks rally up to 40% in 6 months
Sai's management reiterated long-term guidance of 15-20 per cent revenue CAGR with 28-30 per cent steady state EBITDA margin over the next two to three years.
Stocks to buy today: Sudeep Pharma, Rubicon Research, ICICI Prudential AMC
Stocks to buy today: Aakash Shah of Choice Broking has recommended buying three stocks today - Rubicon Research, Sudeep Pharma, and ICICI Prudential Asset Management.
Sunil Singhania’s Abakkus Portfolio: 6 stocks rally up to 75% in CY26; 5 new buys added in Q4
Sunil Singhania’s Abakkus Asset Manager portfolio rose 6% to Rs 2,742 crore in March 2026 quarter, with mixed CY26 performance showing strong gains in Avalon Technologies and Suven Life Sciences amid several notable stock declines.
Eris Life Q4 Results: Stock gains 12% as Domestic Branded Formulations leads growth
The management of Eris Lifesciences said the phased rollout of the semaglutide portfolio, including pen-based products and obesity-focused SKUs, is expected to support growth momentum going ahead.
Here's why today and May 19 are important sessions for Zydus Life shareholders
Zydus Lifesciences will acquire Assertio Holdings for $23.5 per share in cash, valuing the transaction at $166.4 million. Assertio is a US-based specialty pharmaceutical company with a focus on oncology and pain management.
Ruchit Jain of Motilal Oswal suggests Granules India, Nippon Life, and SRF shares to buy for the short term
The Nifty 50 and Sensex increased on May 6, supported by a government credit guarantee scheme for businesses. Investor sentiment improved due to positive earnings reports and falling oil prices, suggesting resilience in markets despite recent challenges.
Enduring wealth, lasting wellness. People in India are living longer. Are they also living well?
India's rising life expectancy faces a longevity paradox, with increased years not always translating to good health, compounded by rising medical inflation and low insurance penetration. Standard Chartered is bridging this gap by integrating health and wealth management through partnerships with Niva Bupa and WHOOP, focusing on proactive wellness and curated experiences for affluent clients.
Sun Pharma a trading play on dips, banks may face difficult June quarter: Dharmesh Kant
Dharmesh Kant, Head of Research at Chola Securities, said Sun Pharma’s all-cash acquisition of Organon could improve return ratios and support valuations, but may bring overall revenue growth down to single digits. He sees a trading opportunity in Sun Pharma on price dips. On banking, he said Q1 could be difficult as provisioning picks up, which may weigh on profitability even as asset quality and margins remain stable. Disclaimer: The views and tips expressed by investment experts on CNBCTV18.com are their own, not of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.
Just Dial Ltd leads losers in 'A' group
Acutaas Chemicals Ltd, Indus Towers Ltd, ICICI Prudential Asset Management Co Ltd and CCL Products (India) Ltd are among the other losers in the BSE's 'A' group today, 15 April 2026.